$INSP

Inspire Medical Systems (INSP) reported a 7.6% revenue decline to $200.6M in Q2, with US sales driving the drop. Despite this, the company boasts an 85.5% gross margin, $415.2M in cash, and raised 2026 revenue guidance to $835M-$875M. The AMA approved new billing codes for its Inspire V system, a key reimbursement milestone. However, the stock trades at a high forward P/E of 59.17, reflecting investor optimism about future earnings.

Inspire Medical Systems (INSP) announced that the AMA CPT Editorial Panel approved new Category I CPT codes for its Inspire V sleep apnea system, effective January 1, 2028. These codes may improve long-term reimbursement clarity and provider workflows. Analysts expect revenue of $991.6M and earnings of $74.2M by 2029, with some optimistic views projecting higher figures. The company's near-term performance depends on center training, contracting, and coding education.

Freedom Capital Markets kept a Buy rating on Inspire Medical Systems with a $97 price target, suggesting 37% upside from the Oct 1 close. The firm cited new CPT code approvals for the Inspire V procedure, which should boost sales growth and investor confidence. The company's focus on physician education and untapped market potential supports the positive outlook.

Inspire Medical Systems (INSP) announced new CPT codes for its Inspire V sleep apnea device, effective January 1, 2028. The codes describe implantation procedures. CMS will determine Medicare payment values, with proposed valuations expected in July 2027. The device is FDA-approved and has treated over 140,000 patients.

Inspire Medical Systems (INSP) announced AMA CPT Editorial Panel approval for new Category I CPT codes covering its Inspire V system. Valuations are expected in 2027, with codes effective January 1, 2028. The approval supports reimbursement clarity and adoption trends for the next-gen system, according to the company.

Inspire Medical Systems (INSP) announced the AMA approved new CPT codes for its Inspire V system, effective January 1, 2028. The company expects this to streamline reimbursement and expand patient access. CMS will determine Medicare payments for the new codes, with proposed valuations expected in July 2027 and final valuations in November 2027.

U.S. stocks ended slightly lower Wednesday as long bond yields rose, but Inspire Medical Systems (INSP) surged 18.95% month-to-date. The medical device company reported Q2 FY2026 earnings beating expectations, with EPS at $0.14 vs. -$0.24 consensus and revenue at $200.6M vs. $194.7M forecast. The stock has climbed 86% since March 2026, driven by strong fundamentals and improving reimbursement trends.

Inspire Medical Systems (INSP) stock is falling due to a 46% year-over-year drop in net income, 7.6% lower revenue, and a projected 71% earnings decline next quarter. Rising costs are squeezing profit margins, raising investor concerns about the company's ability to stabilize earnings. Despite low debt and strong cash flow, insurance reimbursement issues pose risks to future performance.

Analysts adjusted price targets for several companies. Inspire Medical (INSP) raised to $97, Securitize (SECZ) to $13, Cleveland-Cliffs (CLF) to $17.48, Credo (CRDO) cut to $245, Colgate-Palmolive (CL) to $95, TTM (TTMI) to $175, Waters (WAT) to $515, Microsoft (MSFT) to $608, Ciena (CIEN) to $550, T-Mobile (TMUS) to $260.

Freedom Capital Markets kept a Buy rating and $97 price target on Inspire Medical Systems, implying a 26.3% upside. The company reported 14% revenue growth and 27% adjusted EBITDA increase. A new CPT code for the Inspire V procedure may improve reimbursement clarity and sales.